Data integrity verification mechanisms play an important role in cloud environments. Recently, a lightweight identity-based cloud storage audit scheme has been proposed; this paper points out security vulnerabilities of their OffTagGen algorithm. That is, the attackers such as malicious cloud servers can forge the tags, which can destroy data integrity. By improving the construction of OffTagGen algorithm, an improved security cloud auditing protocol is proposed in this work to better protect user’s privacy. The analysis shows that the new protocol is effective and resistant to attacks.
Background
With progress in tumor treatments, patient survival has been significantly extended; nevertheless, tumors and tumor treatments increase the risk of sepsis. Carrimycin may act as an immune-regulating treatment for tumor-related sepsis. We aimed to evaluate whether carrimycin regulates inflammation and immune function in tumor patients with sepsis.
Methods
We conducted a multicenter, randomized, placebo-controlled, double-blind clinical trial involving tumor patients with sepsis. The participant inclusion criteria were as follows: 1. age ≥ 18 and ≤ 75 years old; 2. condition consistent with sepsis 3.0 diagnostic criteria; 3. SOFA score of 2–13; and 4. patients with malignant tumors. Enrolled patients were assigned to either carrimycin treatment (400 mg/day) or placebo treatment (400 mg/day) orally once a day for 7 days. The primary outcome was immune-related indicators.
Results
A total of 120 patients were randomized, of whom 47 were assigned to receive carrimycin and 52 placebo. In immune and inflammation indicators, the HLA-DR and CD8 + T-cell levels showed promising trends, although there was no significant difference between the carrimycin and placebo groups (P > 0.05). In the CD4 < 38.25 subgroup, the HLA-DR level of the carrimycin group was significantly better than that of the placebo group at 1 day after administration (P = 0.023). In the CD8 < 25.195 subgroup, the degree of decrease in IL-8 in the carrimycin group was significantly higher than that in the placebo group at 1 (P = 0.027) and 3 (P = 0.034) days after administration. The CD8 + T-cell subset level of the carrimycin group was significantly better than that of the placebo group at 3 (P = 0.027) and 5 (P = 0.035) days after administration. The levels of SOFA, APACHE II, PCT and CRP were significantly reduced by carrimycin intervention. No serious adverse events were recorded.
Conclusions
In tumor patients with sepsis, especially those with immunocompromised function, carrimycin regulates the immune status by increasing the HLA-DR level and plays an anti-infective role to improve the severity of the disease but does not affect 28-day all-cause mortality.
The trial was registered in the Chinese Clinical Trial Registry (http://www.chictr.org.cn) with the number ChiCTR2000032339 on April 26, 2020.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.